A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It?
A much-awaited treatment for postpartum anxiety, zuranolone, struck the marketplace in December, assuring an available and fast-acting medication for an incapacitating disease. The majority of personal health insurance providers have yet to release requirements for when they will cover it, according to a brand-new analysis of insurance coverage policies.
The absence of assistance might restrict usage of the drug, which is both unique-- it targets hormonal agent function to alleviate signs rather of the brain's serotonin system, as common antidepressants do-- and costly, at $15,900 for the 14-day tablet program.
Legal representatives, supporters, and regulators are enjoying carefully to see how insurer will form policies for zuranolone since of how some managed its predecessor, an...